Armata Pharmaceuticals, Inc.

ARMP

Healthcare|Biotechnology|US

$3.51

+0.51 (+17.00%)

Cash / Share

$0.65

Clinical Trials (13)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT04596319 Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis	Cystic Fibrosis, Pseudomonas Aeruginosa	P1P2	Completed	29	RCT, Double-blind	AP-PA02
NCT05616221 Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection	Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa	P2	Completed	48	RCT, Double-blind	AP-PA02
NCT02594254 Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects	Dental Caries	P2	Completed	135	RCT, Double-blind	C16G2 Gel
NCT03004365 A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects	Dental Caries	P2	Completed	33	RCT, Single-blind	C16G2 Varnish, Placebo Varnish
NCT05184764 Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia	Bacteremia, Staphylococcus Aureus	P1P2	Completed	56	RCT, Double-blind	AP-SA02
NCT03052842 A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application	Dental Caries	P2	Completed	30	RCT, Single-blind	C16G2 Strip
NCT02254993 Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses	Dental Caries	P2	Completed	52	Open-label	C16G2
NCT02044081 Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults	Dental Caries	P2	Completed	60	RCT, Double-blind	C16G2 Rinse, Placebo, C16G2 Gel
NCT03196219 A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects	Dental Caries	P2	Completed	20	RCT, Single-blind	C16G2, Placebo
NCT02509845 Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects	Dental Caries	P2	Completed	64	RCT, Double-blind	C16G2
NCT02757755 Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults	Healthy Volunteers	P1	Completed	12	RCT, Double-blind	AB-SA01 (10^8 PFU per phage), AB-SA01 (10^9 PFU per phage), Placebo (for Cohort 10^8), Placebo (for Cohort 10^9)
NCT03395743 Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic			NO_LONGER_AVAILABLE	—	—	AB-PA01
NCT03395769 Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic			NO_LONGER_AVAILABLE	—	—	AB-SA01